C Partners Holding’s United Therapeutics UTHR Stock Holding History

C Partners Holding’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-969	Closed	-$124K	–	206
2018 Q3	$124K	Sell	969 -1,030	-52%	-$127K	0.04%	115
2018 Q2	$226K	Buy	1,999 +272	+16%	+$29.9K	0.08%	143
2018 Q1	$194K	Sell	1,727 -487	-22%	-$61.9K	0.08%	226
2017 Q4	$328K	Buy	+2,214	New	+$281K	0.13%	24

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

C Partners Holding's UTHR Position: Q4 2018 in Review

C Partners Holding sold out of United Therapeutics (UTHR) in Q4 2018, closing a stake of 969 shares — an estimated $124K sold.

C Partners Holding first reported a position in UTHR in Q4 2017 and held it in 4 quarters. The position peaked at $328K in Q4 2017. 360 funds tracked by Wall St. Rank hold UTHR as of Q4 2018.

C Partners Holding reported no remaining United Therapeutics position as of Q4 2018 after selling out during the quarter.
C Partners Holding sold 969 United Therapeutics shares in Q4 2018, an estimated $124K.
C Partners Holding first reported a position in United Therapeutics in Q4 2017 and held it in 4 quarters.
C Partners Holding's United Therapeutics position peaked at $328K in Q4 2017.
360 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2018.

Based on C Partners Holding's 13F filing for Q4 2018, filed 7 Feb 2019.